Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 08, 2022

Intralesional SD-101 in Combination With Pembrolizumab in Anti–PD-1 Treatment-Naive HNSCC

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive head and neck squamous cell carcinoma: results from a multicenter, phase 2 trial
Clin. Cancer Res 2021 Dec 29;[EPub Ahead of Print], EEW Cohen, L Nabell, DJ Wong, T Day, GA Daniels, M Milhem, S Deva, M Jameson, O Guntinas-Lichius, M Almubarak, M Strother, E Whitman, M Chisamore, C Obiozor, T Bagulho, J Gomez-Romo, C Guiducci, R Janssen, E Gamelin, AP Algazi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading